Be Aware of Finerenone's Role for Diabetic Kidney Disease

Finerenone (Kerendia) will be a new Rx for patients with chronic kidney disease (CKD) due to type 2 diabetes.

It's the first "nonsteroidal mineralocorticoid receptor antagonist"...and is approved to slow CKD progression and improve CV outcomes in these patients.

Finerenone is thought to limit fibrosis and inflammation in the kidneys and heart...by blocking effects of aldosterone.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote